arrow
N

Ning Wu

首都医科大学
H指数:41
被引数:5,868

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II Trial of Neoadjuvant Camrelizumab and Apatinib in Resectable NSCLC: 3-year Survival Outcomes and Dynamic Circulating Tumor DNA Analyses

可切除非小细胞肺癌新辅助治疗中卡瑞利珠单抗联合阿帕替尼的II期试验:3年生存结局与动态循环肿瘤DNA分析

2025-12-240
PRE
18F-FDG PET/CT for prediction of PD-L1 expression and tumor mutational burden in non-small cell lung cancer: biomarkers prediction models development and immunotherapy responses verification

18F-FDG PET/CT在预测非小细胞肺癌PD-L1表达和肿瘤突变负荷中的应用:生物标志物预测模型开发及免疫治疗反应验证

2025-11-280
OAAI
Corrigendum to Deep learning model based on primary tumor to predict lymph node status in clinical stage IA lung adenocarcinoma: a multicenter study [Journal of the National Cancer Center 4 (2024) 233–240]

勘误:基于原发肿瘤预测临床IA期肺腺癌淋巴结状态的深度学习模型:一项多中心研究 [国家癌症中心杂志 4 (2024) 233–240]

2025-10-250
OAAI
A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer
2025-04-170
OAAI
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
2024-02-291
OAAI